The PROOF 302 Trial is now enrolling. Eligible study participants will be randomized in a 1:1 ratio to receive either infigratinib or a placebo. The assigned study treatment will be administered orally once daily for the first 3 weeks (21 days) of a 28-day treatment cycle for a maximum of 52 weeks.
If an individual’s FGFR3 status is unknown, they will be offered molecular testing as part of the prescreening procedures to determine whether their tumor contains the FGFR3 genetic alteration.